Skip to content

Wrinkle Injection With Autologous Platelet Rich Plasma Study

Phase 1 Study of Intradermal Injection of Autologous Platelet Rich Plasma for Facial Wrinkles

Status
Withdrawn
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01078493
Acronym
WIPES
Enrollment
0
Registered
2010-03-02
Start date
2010-02-28
Completion date
2012-05-31
Last updated
2016-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wrinkles

Keywords

Platelet rich plasma, PRP, wrinkles, MyCells®, CREATE, Life Source Medical Centre, Dr Tan Kok leong

Brief summary

Wrinkles result from imperfect repair of the dermal layer resulting in loss of collagen commonly due to ageing, smoking and sun exposure. Platelet rich plasma (PRP) contains a host of growth factors, which have been used in other clinical trials for various medical conditions such as tendonitis, and also in surgery such as the surgical repair of facial defects. Results from these clinical trials suggest that PRP helps in collagen formation and organisation to promote healing of tissues. This study attempts to document the clinical effects of intradermal injection of PRP on wrinkles.

Detailed description

10 selected participants will have 10 ml of blood removed for platelet extraction with MyCells®. The resulting Platelet rich plasma will be injected intradermally into the facial wrinkles.

Interventions

DEVICEMyCells® (injection of platelet rich plasma)

PRP contains at least 1,000,000 platelets per mm3 or 2-6 times the native concentration of whole blood at a pH of 6.5 to 6.7

Sponsors

Novena Medical Center
Lead SponsorNETWORK

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adults more than 21 years of age * Dis-satisfied or anxious about facial wrinkles (total wrinkle length more than 1cm)

Exclusion criteria

* Pregnant women. * Psychiatric patients. * Known bleeding disorders such as platelet dysfunction syndrome, thrombocytopenia, hypofibrinogenemia * Anticoagulants(eg.aspirin, warfarin) * Had other wrinkle therapy for less than a month.(laser, peels, injections) * Had facelift surgery for less than a year. * Diseased states such as organ failure, severe anaemia, cancer, acute/chronic infections. * Involved in personal litigation against an aesthetic service provider

Design outcomes

Primary

MeasureTime frameDescription
Total Wrinkle Length3 monthsAll visible wrinkles are measured and the length is summed up to give the Total Wrinkle Length. Comparison of pre treatment and post treatment Total Wrinkle Length will be studied.

Secondary

MeasureTime frameDescription
Side effect / Adverse Event3 monthsSide Effects / Adverse Events to be monitored include allergic reaction, nerve injury and cavernous sinus thrombosis.

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026